STRENSIQ 40 mg/ml

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines, as this will also vary.

Adults: Refer to specific drug information for dosing guidelines, as this will vary widely.

Mechanism of action

The mechanism of action for 'alfa' cannot be defined without specific identification of the drug. Each compound named 'alfa' will have distinct mechanisms, typically involving receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Pharmacodynamics

Pharmacodynamics will vary widely depending on the specific agent referred to as 'alfa'. Generally, pharmacodynamics describes how a drug affects the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect.

Pharmacokinetics

The pharmacokinetics of 'alfa' would also depend on the particular drug profile, including absorption, distribution, metabolism, and excretion (ADME). Parameters such as bioavailability, half-life, and clearance rates would need to be defined based on the specific agent.

Pregnancy

Consult healthcare provider for risk assessment.

Breast-feeding

Consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Hypophosphatasia
• Deficiency of alkaline phosphatase

Dosage

Children: Refer to specific guidelines and clinical protocols for pediatric dosing as asfotase therapy is individualized based on the child's condition and response.

Adults: Refer to specific prescribing guidelines and clinical protocols for adult dosing as asfotase is typically tailored to the individual patient's needs.

Mechanism of action

Asfotase works by providing a functional form of alkaline phosphatase, which catalyzes the hydrolysis of phosphate esters and plays a vital role in the mineralization of bones and teeth. It helps to increase the availability of inorganic phosphate, which is essential for bone formation and maintenance. This therapeutic enzyme directly addresses the biochemical deficiency caused by mutations in the ALPL gene, leading to improvements in skeletal health.

Pharmacodynamics

Asfotase exhibits its effects through the restoration of alkaline phosphatase activity, which is essential for normal bone metabolism. By facilitating the hydrolysis of pyrophosphate, it enhances mineralization and promotes healthy bone structure. In clinical studies, treatment with asfotase has been shown to improve bone density, reduce fractures, and enhance overall physical function in patients with hypophosphatasia.

Pharmacokinetics

Asfotase is administered via subcutaneous injection. Once injected, it is absorbed into the systemic circulation, where it exerts its therapeutic effects. The pharmacokinetics of asfotase, including its half-life, distribution, metabolism, and excretion, are influenced by factors such as age and body weight. Generally, it is cleared from circulation through a combination of proteolytic degradation and renal excretion, but specific pharmacokinetic parameters may vary among patients.

Adverse effects

• Injection site reactions
• Hypersensitivity reactions
• Fever
• Headache
• Nausea
• Vomiting
• Diarrhea
• Fatigue

Precautions

• Caution in patients with a history of hypersensitivity to asfotase or any component of the formulation
• Monitor for signs of allergic reactions
• Use with caution in patients with pre-existing conditions that may be exacerbated by the drug

Pregnancy

The safety of asfotase in pregnancy has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether asfotase is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Formulations

• Asfotase alfa injection